{"id":"W4319922981","doi":"10.1016/j.ejca.2023.02.002","title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; PharmaMar; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Eisai; Genomic Health; Fondation ARC pour la Recherche sur le Cancer; Seagen; Genentech; Veracyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Medpace; Puma Biotechnology; Regeneron Pharmaceuticals; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Kræftens Bekæmpelse; European Commission; Exelixis; Amgen; Pfizer; Celgene","keywords":"Neratinib; Trastuzumab; Medicine; Placebo; Oncology; Breast cancer; Internal medicine; Pertuzumab; Adjuvant; Adjuvant therapy; Double blind; Cancer; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003836355,0.0004806589,0.001484875,0.0006333779,0.00009569678,0.0001406892,0.000350679,0.00007477766,0.002051251],"category_scores_gemma":[0.00007712314,0.0003161684,0.0004673698,0.0007713653,0.0002016473,0.0002137268,0.00003891519,0.001154706,0.00004012928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006496776,"about_ca_system_score_gemma":0.002613805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003886812,"about_ca_topic_score_gemma":0.0005307107,"domain_scores_codex":[0.9942933,0.001461751,0.001318812,0.0004859032,0.00164254,0.0007977149],"domain_scores_gemma":[0.997339,0.0003172271,0.0006088594,0.0003687463,0.0008274446,0.0005387394],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9373586,0.0006910278,0.001767751,0.00005251472,0.0007266706,0.004834051,0.0008678191,0.002756794,0.001383935,0.00000213341,0.002468398,0.04709037],"study_design_scores_gemma":[0.9758629,0.005986535,0.009231945,0.001379304,0.0002355957,0.0001278071,0.0001266126,0.0006860642,0.0008087153,0.000002242489,0.005192996,0.000359311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830586,0.003668194,0.0001407544,0.006102722,0.001042829,0.003835435,0.0001529604,0.00004774714,0.001950708],"genre_scores_gemma":[0.9910945,0.002358649,0.00008203492,0.0009691576,0.003253525,0.0006101033,0.00001521958,0.0001884046,0.001428354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04673106,"threshold_uncertainty_score":0.999929,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0521616362129542,"score_gpt":0.3818282319083606,"score_spread":0.3296665956954064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}